Capillary Biomedical, Inc.

5 articles about Capillary Biomedical, Inc.

• Capillary Biomedical Receives ISO 13485:2016 Quality System Certification

  3/1/2022

  Medical device developer Capillary Biomedical, Inc. has announced that it has received ISO 13485:2016 certification, indicating that CapBio’s quality management system conforms to the recognized international standard for the design, manufacture, and distribution of medical devices.

• Capillary Biomedical Receives FDA Approval to Begin Pivotal Trial of Its SteadiFlow Seven-Day-Wear Infusion Set Technology

  1/19/2022

  Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to start a pivotal trial for the assessment of its SteadiFlow seven-day-wear infusion set technology.

• Capillary Biomedical Receives $1.5 Million from Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology

  10/7/2020

  Capillary Biomedical, Inc. (CapBio) has announced that it has received a $1.5 million program-related investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley). The use of funds includes clinical studies of CapBio’s

• Capillary Biomedical Closes $2.9 Million Series Seed Financing for Commercialization of Novel Insulin Infusion Technology

  8/14/2018

  Funding boosts development of breakthrough infusion set designed to eliminate failures and improve the quality of life for millions of diabetics

• Capillary Biomedical Sheds Light On The Mechanical Challenges Of Insulin Pump Delivery Systems At Annual American Diabetes Association Scientific Sessions

  6/14/2017